Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
Background:
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people
with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers
want to add another drug to standard treatment see if it can improve the cure rate.
Objective:
To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy
can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell
lymphoma.
Eligibility:
People ages 18 and older with an aggressive B-cell lymphomas that have not been treated
Design:
Participants will be screened with:
Blood and urine tests
Physical exam
Medical history
Tumor biopsy
Bone marrow biopsy: A needle will remove marrow from the participant s hipbone.
Lumbar puncture: If necessary, a needle will remove fluid from the participant s spinal
canal.
Imaging scans
Participants will take the study drug for up to 14 days. It is a pill taken 2 times a day.
Then they will have more scans. They will get rituximab and chemotherapy. They may get these
drugs through a needle in an arm vein. Or they may them through a tube placed in a vein in
their chest or in their neck. They might also keep taking the study drug. Each treatment
cycle lasts 21 days. They will have up to 6 cycles.
Participants may have 4 doses of another drug injected into their spinal fluid.
Participants will have repeats of the screening tests throughout the study.
Participants will have a follow-up visit 30 days after their last treatment, then every 3
months for 2 years, then every 6 months for 3 years, and then yearly.
...